AMINOPYRIDINE KINASE INHIBITORS

• US 20110183966A1
• Filed: 02/04/2011
• Published: 07/28/2011
• Est. Priority Date: 08/06/2008
• Status: Active Grant

• Current Assignee: Vertex Pharmaceuticals Incorporated
• Original Assignee: Vertex Pharmaceuticals Incorporated
• Inventors: Young, Stephen, Boyall, Dean, Maltais, Francois, Settimo, Luca, Davis, Christopher John, Jimenez, Juan Miguel, Bemis, Guy W., Wang, Tiansheng, Fraysse, Damien
• Granted Patent: US 8,377,926 B2
• Time in Patent Office: Days
• US Class Current: 514/218
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 213/73 Unsubstituted amino or imino radicals
• CPC Class Codes: C07D 213/74 Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• CPC Class Codes: C07D 401/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 401/10 linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 407/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 407/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 417/14 : containing three or more hetero rings

Abstract

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

Claims

1. A compound represented by a structural formula selected from the group consisting of:

3. A composition comprising a compound or pharmaceutically acceptable salt thereof according to any one of claims 1-2, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

4. A method of treating or preventing a protein kinase-mediated condition in a subject, comprising administering to the subject an effective amount of a compound or pharmaceutically acceptable salt thereof or composition of any one of claims 1-3.

5. The method of claim 4, wherein the protein kinase-mediated condition is a PKC mediated condition.

6. The method of claim 5, wherein the PKC-mediated condition is a PKCtheta mediated condition.

7. The method of claim 6, wherein the PKCtheta mediated condition is an autoimmune disease, an inflammatory disease or a proliferative or hyperproliferative disease.

8. The method of claim 7, wherein the PKCtheta mediated condition is selected from the group consisting of asthma, psoriasis, arthritis, rheumatoid arthritis, joint inflammation, multiple sclerosis, diabetes, inflammatory bowel disease, transplant rejection, T-cell leukaemias, lymphomas, and lupus.

9. The method of claim 8, wherein the PKCtheta mediated condition is an autoimmune disease.

10. The method of claim 9, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, irritable bowel disease

11. The method of claim 10, wherein the autoimmune disease is multiple sclerosis.

12. The method of claim 10, wherein the autoimmune disease is rheumatoid arthritis.

13. The method of claim 10, wherein the autoimmune disease is irritable bowel disease.

14. The method of claim 7, wherein the PKCtheta mediated condition is selected from the group consisting of T-cell leukaemia and lymphoma.

2. A compound represented by a structural formula selected from the group consisting of: